Boehringer Ingelheim revealed new results from its Phase IIb EFFIOSAYIL 2 trial that shows its new antibody-based therapeutic Spevigo can prevent flare-ups in a rare and severe form of psoriasis, generalized postular psoriasis (GPP). The drug is the first treatment to be approved for the disabling and sometimes life-threatening condition.
According to Nicole Defeudis, “While most patients enrolled in a Phase II pivotal trial had a “high or very high” density of pustules, 54% showed no visible pustules after a week of treatment with Spevigo, compared to 6% of those on a placebo, according to Boehringer. The EFFISAYIL 2 trial showed a ‘significant prevention of generalized pustular psoriasis (GPP) flares for up to 48 weeks’ in adolescents and adults, the company said on Monday.”
To read more, click here.
(Source: Endpoints News, January 30th, 2023)
